HSV-TK/IL-2 gene therapy for glioblastoma multiforme.
We performed a clinical trial of gene therapy in patients with recurrent glioblastoma multiforme based on retroviral vector-mediated combined delivery of interleukin-2 and thymidine kinase of herpes simplex virus (HSV)-1. Treatment consisted of intratumor injection of retroviral vector-producing cells, followed by intravenous ganciclovir administration. The primary endpoints of the study were the evaluation of the safety of the treatment and demonstration of transduction of tumor cells. Here, we report details on the clinical protocol and the methods used.
Barzon
Luisa
L
Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy.
Pacenti
Monia
M
Franchin
Elisa
E
Colombo
Federico
F
Palù
Giorgio
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000379:methods*; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D005909:Glioblastoma / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics* / Q000627:therapeutic use*; D008875:Middle Aged; D018579:Patient Selection; D012190:Retroviridae / Q000235:genetics; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000235:genetics* / Q000627:therapeutic use; D014161:Transduction, Genetic
D007376:Interleukin-2; D013937:Thymidine Kinase